...
首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >P53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells
【24h】

P53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells

机译:P53siRNA治疗减少三阴性乳腺癌细胞的细胞增殖,迁移并诱导凋亡

获取原文
获取原文并翻译 | 示例
           

摘要

p53 protein is probably the best known tumor suppressor. Earlier reports proved that human breast cancer cells expressing mutant p53 displayed resistance to apoptosis. This study is intended to investigate, the potential applications of RNA interference (RNAi) to block p53 expression, as well as its subsequent effect on cell growth, apoptosis and migration on a triple negative human breast cancer cell line (Hs578T). p53siRNA significantly reduced cell index (CI) compared to the control and we observed an inhibition of cellular migration in the interval of time between 0 and 30 h, as shown in the data obtained by dynamic evaluation using the xCELLigence System. Also, by using PCR-array technology, a panel of 84 key genes involved in apoptosis was investigated. Our studies indicate that the knockdown of p53 expression by siRNA modulates several genes involved in cell death pathways and apoptosis, showing statistically significant gene expression differences for 22 genes, from which 18 were upregulated and 4 were downregulated. The present research also emphasizes the important role of BCL-2 pro-apoptotic family of genes (Bim, Bak, and Bax) in activating apoptosis and reducing cell proliferation by p53siRNA treatment. Death receptors cooperate with BCL-2 pro-apoptotic genes in reducing cell proliferation. The limited success may be due to the activation of the antiapoptotic gene Mcl-1, and it may be associated with the resistance of triple negative breast cancer cells to cancer treatment. Thus, targeting p53siRNA pathways using siRNA may serve as a promising therapeutic strategy for the treatment of breast cancers.
机译:p53蛋白可能是最广为人知的肿瘤抑制因子。较早的报道证明,表达突变型p53的人乳腺癌细胞显示出对凋亡的抗性。这项研究旨在研究RNA干扰(RNAi)阻断p53表达的潜在应用,以及其对三阴性人类乳腺癌细胞系(Hs578T)细胞生长,凋亡和迁移的后续影响。与对照相比,p53siRNA显着降低了细胞指数(CI),我们观察到在0到30小时之间的时间间隔内细胞迁移受到抑制,如使用xCELLigence系统进行动态评估获得的数据所示。此外,通过使用PCR阵列技术,研究了一组涉及凋亡的84个关键基因。我们的研究表明,通过siRNA抑制p53表达可调节参与细胞死亡途径和细胞凋亡的几个基因,显示22个基因在统计学上有显着差异,其中18个上调而4个下调。本研究还强调了BCL-2促凋亡基因家族(Bim,Bak和Bax)在通过p53siRNA处理激活细胞凋亡和减少细胞增殖中的重要作用。死亡受体与BCL-2促凋亡基因协同减少细胞增殖。有限的成功可能是由于抗凋亡基因Mcl-1的激活所致,并且可能与三阴性乳腺癌细胞对癌症治疗的抗性有关。因此,使用siRNA靶向p53siRNA途径可作为治疗乳腺癌的有前途的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号